NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -0.07
Percentage change -1.90	%

Peers: REGN AMGN VRTX MRNA BNTX INCY ALNY NVAX IONS EXEL

| Held by: IBB IDNA SPDW ONEQ GWX LRNZ AVUS AVSC BBC PDN

Index	-	P/E	-	EPS (ttm)	-0.57	Insider Own	24.97%	Shs Outstand	298.36M	Perf Week	-8.56%
Market Cap	1.00B	Forward P/E	-	EPS next Y	-0.55	Insider Trans	0.00%	Shs Float	223.95M	Perf Month	66.58%
Enterprise Value	441.98M	PEG	-	EPS next Q	-0.14	Inst Own	41.08%	Short Float	11.84%	Perf Quarter	50.90%
Income	-167.87M	P/S	43.44	EPS this Y	-10.77%	Inst Trans	12.81%	Short Ratio	5.03	Perf Half Y	11.06%
Sales	23.12M	P/B	0.98	EPS next Y	10.02%	ROA	-11.96%	Short Interest	26.52M	Perf YTD	14.85%
Book/sh	3.43	P/C	1.59	EPS next 5Y	0.83%	ROE	-15.59%	52W High	4.09 -17.63%	Perf Year	16.84%
Cash/sh	2.11	P/FCF	-	EPS past 3/5Y	- -107.74%	ROIC	-15.45%	52W Low	1.89 77.99%	Perf 3Y	-68.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-57.49% 19.95%	Gross Margin	-318.94%	Volatility	9.64% 8.90%	Perf 5Y	-
Dividend TTM	-	EV/Sales	19.12	EPS Y/Y TTM	-12.26%	Oper. Margin	-1395.34%	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.15	Sales Y/Y TTM	-35.41%	Profit Margin	-726.23%	RSI (14)	60.83	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	10.15	EPS Q/Q	-10.45%	SMA20	7.23%	Beta	0.62	Target Price	8.33
Payout	-	Debt/Eq	0.07	Sales Q/Q	-57.45%	SMA50	30.52%	Rel Volume	1.36	Prev Close	3.43
Employees	596	LT Debt/Eq	0.06	Earnings	May 08 AMC	SMA200	24.14%	Avg Volume	5.27M	Price	3.37
IPO	Dec 11, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-10.21% -41.49%	Trades		Volume	567,284	Change	-1.90%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-24	Downgrade	The Benchmark Company	Buy → Hold
Feb-22-24	Upgrade	The Benchmark Company	Hold → Buy	$9
Dec-05-23	Initiated	KeyBanc Capital Markets	Overweight	$6
Nov-06-23	Downgrade	The Benchmark Company	Buy → Hold
Oct-13-23	Resumed	Piper Sandler	Overweight	$20
Feb-28-23	Initiated	Cowen	Outperform
Dec-15-22	Initiated	Goldman	Buy	$30
Nov-16-22	Initiated	Truist	Buy	$29
Dec-21-21	Initiated	The Benchmark Company	Buy	$27
Nov-19-21	Initiated	Piper Sandler	Overweight	$33
Jan-05-21	Initiated	SVB Leerink	Outperform	$45
Jan-05-21	Initiated	Stifel	Buy	$59
Jan-05-21	Initiated	Credit Suisse	Outperform	$52
Jan-05-21	Initiated	BMO Capital Markets	Outperform	$48
Jan-05-21	Initiated	Berenberg	Buy	$53

Show Previous Ratings

Jun-25-25 04:09AM	AbCellera Biologics Secures Patent Validity Affirmation for Microfluidic Cell Culture Technology (Insider Monkey)
Jun-09-25 09:13AM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
Jun-03-25 12:00PM	ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why (Zacks) +7.94%
Jun-02-25 06:45PM	Why AbCellera Biologics Stock Raced Nearly 6% Higher Today (Motley Fool) +5.94%
May-30-25 01:00PM	AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 (Business Wire)
11:21AM	Loading…
May-21-25 11:21AM	AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential (Insider Monkey)
May-14-25 05:00PM	AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause (Business Wire)
May-12-25 03:30PM	AbCelleras Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit (Business Wire)
May-09-25 07:30PM	AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting (Business Wire)
11:22AM	Q1 2025 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
03:50AM	AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-08-25 06:05PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q1 2025 Business Results (Business Wire)
May-07-25 12:39PM	AbCellera Biologics Q1 2025 Earnings Preview (Seeking Alpha)
10:45AM	AbCellera Biologics Inc (ABCL) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
03:00PM	Loading…
Apr-29-25 03:00PM	AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 (Business Wire)
Apr-23-25 10:14AM	Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now? (Insider Monkey)
Apr-16-25 11:59PM	AbCellera: Attractively Priced But A Catalyst Is Needed (Seeking Alpha)
Apr-08-25 04:05PM	AbCellera to Participate at Upcoming Investor Conferences in May and June (Business Wire) -5.85% +12.44%
Apr-03-25 04:05PM	AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire) -5.86%
Mar-25-25 04:30PM	AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 (Business Wire)
Feb-28-25 02:18PM	Q4 2024 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -11.47%
02:43AM	AbCellera Biologics Inc (ABCL) Q4 2024 Earnings Call Highlights: Strategic Shifts Amid ... (GuruFocus.com)
Feb-27-25 10:15PM	AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript (Motley Fool)
06:15PM	AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Full Year 2024 Business Results (Business Wire)
Feb-26-25 07:55AM	What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earnings (GuruFocus.com)
Feb-11-25 04:05PM	AbCellera to Participate at Upcoming Investor Conferences in March (Business Wire) +5.08%
Jan-21-25 04:05PM	AbCellera to Report Full Year 2024 Financial Results on February 27, 2025 (Business Wire) +15.36%
Jan-17-25 07:53AM	AbCellera Biologics Inc. (ABCL): A Bull Case Theory (Insider Monkey)
10:47AM	Loading…
Jan-15-25 10:47AM	AbbVie and Simcere Zaiming link to develop trispecific antibody (Pharmaceutical Technology) +6.86%
Jan-14-25 09:25AM	AbCellera expands collaboration with AbbVie (TipRanks) -7.67%
Jan-13-25 09:00AM	AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology (Business Wire)
Jan-07-25 09:11AM	Is AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts? (Insider Monkey)
Nov-21-24 04:05PM	AbCellera to Present at Upcoming Investor Conferences in December and January (Business Wire)
Nov-07-24 10:05AM	AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 (Business Wire)
Nov-05-24 11:17AM	Q3 2024 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents) -5.88%
02:11AM	AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
Nov-04-24 11:00PM	AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript (Motley Fool) +5.86%
05:55PM	AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q3 2024 Business Results (Business Wire)
Nov-01-24 09:06AM	AbCellera Biologics Inc (ABCL) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-22-24 04:05PM	AbCellera to Present at Upcoming Investor Conferences in November 2024 (Business Wire)
Oct-16-24 08:58AM	Is AbCellera Biologics Inc. (ABCL) the Penny Stock with the Biggest Upside Potential According to Analysts? (Insider Monkey)
Oct-04-24 09:00AM	AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024 (Business Wire)
Sep-26-24 04:05PM	AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024 (Business Wire)
Sep-01-24 10:26PM	AbCellera Biologics Inc. (ABCL): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
04:05PM	AbCellera to Present at Upcoming Investor Conferences in September (Business Wire)
05:13AM	AbCellera Biologics Inc. (ABCL): A Top Contender Among Canadas Best Penny Stocks in 2024 (Insider Monkey)
Aug-07-24 12:45AM	AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript (Motley Fool) -7.72%
Aug-06-24 06:15PM	AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AbCellera Reports Q2 2024 Business Results (Business Wire)
Aug-01-24 06:32AM	AbCellera and Lilly broadens antibody discovery partnership (Pharmaceutical Technology) -6.44%
Jul-31-24 09:00AM	AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines (Business Wire)
Jul-21-24 05:37AM	Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? (Motley Fool)
Jul-09-24 12:00PM	AbCellera Biologics (ABCL) Upgraded to Buy: Here's What You Should Know (Zacks)
Jun-25-24 04:05PM	AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jun-13-24 05:40AM	Down 57%, Is AbCellera Biologics a Buy on the Dip? (Motley Fool)
May-28-24 04:05PM	AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024 (Business Wire) +5.97%
May-13-24 06:00AM	3 Stock Gems Hiding in the Nasdaq (InvestorPlace)
May-08-24 11:03AM	AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:01AM	Q1 2024 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
04:30AM	AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript (Motley Fool)
May-07-24 08:57PM	ABCL Stock Earnings: AbCellera Biologics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:05PM	AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:01PM	AbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss Estimates (GuruFocus.com)
04:05PM	AbCellera Reports Q1 2024 Business Results (Business Wire)
May-01-24 09:00AM	AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies (Business Wire)
Apr-30-24 10:01AM	Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for (Zacks)
Apr-08-24 12:05PM	AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 (Business Wire)
Apr-03-24 04:05PM	AbCellera to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Mar-27-24 04:30PM	The 7 Best Penny Stocks to Buy in Q2 2024 (InvestorPlace)
Mar-26-24 05:25PM	Billionaire Investor Stan Druckenmiller and Insiders Are Piling Into These 11 Stocks (Insider Monkey) -6.33%
Mar-19-24 04:05PM	AbCellera to Present at the Bloom Burton Healthcare Conference on April 16, 2024 (Business Wire)
Mar-11-24 09:00AM	AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions (Business Wire)
Mar-05-24 04:30PM	AbCellera Announces Four Presentations on T-Cell Engagers at AACR 2024 (Business Wire)
Feb-26-24 06:55AM	3 Highly Rated Biotech Stocks to Buy for 300% Gains (InvestorPlace)
Feb-23-24 04:30PM	AbCellera Announces Resignation of Board Member (Business Wire)
Feb-22-24 08:15PM	AbCellera to Present at Upcoming Investor Conferences in March (Business Wire)
Feb-21-24 09:22AM	AbCellera Biologics Inc. (NASDAQ:ABCL) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.42%
07:09AM	Q4 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-20-24 11:00PM	AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript (Motley Fool)
07:00PM	AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:57PM	AbCellera Biologics Inc (ABCL) Faces Net Loss in FY 2023 Amid Strategic Shifts (GuruFocus.com)
04:05PM	AbCellera Reports Full Year 2023 Business Results (Business Wire)
Jan-30-24 01:02PM	Baillie Gifford Adjusts Stake in AbCellera Biologics Inc (GuruFocus.com) -5.55%
Jan-23-24 04:05PM	AbCellera to Report Full Year 2023 Financial Results on February 20, 2024 (Business Wire)
Jan-15-24 09:30AM	3 Growth Stocks That Could Go Parabolic in 2024 (Motley Fool)
Jan-03-24 09:40AM	Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-20-23 04:05PM	AbCellera to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024 (Business Wire)
Dec-16-23 01:00PM	AI Meets Biotech: 3 Top Stocks Transforming Medical Science (InvestorPlace)
Dec-11-23 03:30PM	16 Best Penny Stocks To Buy For 2024 (Insider Monkey)
Nov-16-23 04:05PM	AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023 (Business Wire)
Nov-03-23 12:05PM	AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023 (Business Wire) +6.09%
10:51AM	AbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2023 Earnings Call Transcript (Insider Monkey)
08:42AM	Q3 2023 Abcellera Biologics Inc Earnings Call (Thomson Reuters StreetEvents)
05:55AM	Prelude Therapeutics Inc (PRLD) Reports Q3 Financial Results and Strategic Pipeline Progress (GuruFocus.com)
05:30AM	AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript (Motley Fool)
Nov-02-23 05:56PM	AbCellera Biologics Inc (ABCL) Reports Q3 2023 Earnings: Revenue Drops to $7 Million (GuruFocus.com) +7.52%

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Veronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Open in Screener

ETNB

89bio Inc

Jul 01 • 09:42AM ET

9.82

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: AKRO MDGL VKTX GNFT CENTA CGEN NBIX GILD VYGR PRTA

| Held by: VTI IWM VXF XBI IBB IWN SCHA VTWO IWO VHT

Index	RUT	P/E	-	EPS (ttm)	-3.38	Insider Own	3.20%	Shs Outstand	145.98M	Perf Week	0.05%
Market Cap	1.43B	Forward P/E	-	EPS next Y	-2.23	Insider Trans	122.08%	Shs Float	141.32M	Perf Month	-0.20%
Enterprise Value	832.36M	PEG	-	EPS next Q	-0.50	Inst Own	106.18%	Short Float	9.90%	Perf Quarter	35.08%
Income	-386.67M	P/S	-	EPS this Y	41.09%	Inst Trans	44.23%	Short Ratio	6.76	Perf Half Y	22.60%
Sales	0.00M	P/B	2.37	EPS next Y	-7.89%	ROA	-61.26%	Short Interest	13.99M	Perf YTD	25.58%
Book/sh	4.15	P/C	2.24	EPS next 5Y	13.99%	ROE	-69.30%	52W High	11.84 -17.06%	Perf Year	30.24%
Cash/sh	4.38	P/FCF	-	EPS past 3/5Y	7.88% 32.21%	ROIC	-60.20%	52W Low	4.16 136.06%	Perf 3Y	183.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.00% 5.48%	Perf 5Y	-57.06%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-68.13%	Oper. Margin	-	ATR (14)	0.52	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	18.03	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.28	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	18.03	EPS Q/Q	9.68%	SMA20	-2.02%	Beta	1.51	Target Price	30.30
Payout	-	Debt/Eq	0.06	Sales Q/Q	-	SMA50	10.03%	Rel Volume	0.30	Prev Close	9.82
Employees	93	LT Debt/Eq	0.06	Earnings	May 01 AMC	SMA200	17.09%	Avg Volume	2.07M	Price	9.82
IPO	Nov 11, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	11.49% -	Trades		Volume	49,204	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-14-25	Initiated	Goldman	Neutral	$11
Mar-13-25	Initiated	Citigroup	Buy	$25
Feb-04-25	Initiated	Wolfe Research	Outperform
Apr-22-24	Resumed	BofA Securities	Buy	$30
Jan-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$24 → $15
Oct-10-23	Downgrade	Oppenheimer	Outperform → Perform
Aug-28-23	Initiated	UBS	Buy	$36
Jun-13-23	Initiated	Evercore ISI	Outperform	$49
May-12-22	Upgrade	Raymond James	Outperform → Strong Buy	$33 → $12
Dec-20-21	Initiated	H.C. Wainwright	Buy	$46
Oct-26-21	Resumed	Cantor Fitzgerald	Overweight	$49
Jul-29-21	Resumed	BTIG Research	Buy	$60
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform	$65 → $35
Apr-21-21	Initiated	Cantor Fitzgerald	Overweight	$58
Oct-19-20	Initiated	Raymond James	Strong Buy	$65
Sep-25-20	Upgrade	BofA Securities	Neutral → Buy	$37 → $43
Jul-31-20	Initiated	Piper Sandler	Overweight	$54
Jul-23-20	Initiated	BTIG Research	Buy
Jul-07-20	Initiated	Chardan Capital Markets	Buy	$58
Dec-09-19	Initiated	SVB Leerink	Outperform

Show Previous Ratings

Jun-06-25 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-25 04:05PM	89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-13-25 08:46AM	Why 89bio, Inc. (ETNB) Is Among the Best Low Priced Biotech Stocks to Buy Now (Insider Monkey)
May-09-25 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.32%
May-06-25 04:05PM	89bio to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.99%
04:05PM	Loading…
May-01-25 04:05PM	89bio Reports First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire) +7.38%
Apr-24-25 06:31AM	Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips (Zacks)
Apr-18-25 04:46AM	89bio: A Buy With Strong Market Opportunity In MASH And SHTG (Seeking Alpha)
Apr-17-25 10:28AM	89bio: Primary Asset Targeting 2 Potential Indications And Is In Late-Stage Development (Seeking Alpha)
Apr-10-25 01:07PM	Vaxcyte Stock Plummets 56% in a Month: Here's the Reason (Zacks) -9.84%
07:00AM	VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study (Zacks)
Apr-08-25 06:55AM	VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe (Zacks) -12.02%
06:46AM	FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug (Zacks)
Apr-03-25 10:14AM	BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study (Zacks)
Apr-02-25 10:18AM	LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? (Zacks) +5.81%
11:20AM	Loading…
Mar-28-25 11:20AM	FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda (Zacks) -9.82%
Mar-26-25 07:58AM	GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection (Zacks)
02:06AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised) (Zacks)
Mar-25-25 09:40AM	Is Creative Medical Technology Holdings, Inc. (CELZ) Stock Outpacing Its Medical Peers This Year? (Zacks) -12.46%
07:56AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Zacks)
Mar-21-25 01:03PM	Elevation Oncology Plunges 42% on Ending Development of Lead Drug (Zacks)
01:01PM	Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering (Zacks)
Mar-13-25 11:34AM	Citi says SMid biotechs alternative to large caps as it starts coverage (Investing.com)
Mar-12-25 09:55AM	Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now (Zacks) +10.74%
Mar-03-25 04:05PM	89bio to Participate in the Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-27-25 04:05PM	89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates (GlobeNewswire)
Feb-20-25 09:55AM	Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High? (Zacks)
09:55AM	Should You Buy 89BIO (ETNB) After Golden Cross? (Zacks)
Feb-06-25 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-03-25 08:00AM	89bio Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
10:31PM	Loading…
Jan-28-25 10:31PM	89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
04:59PM	Why 89bio Stock Lagged the Market Today (Motley Fool)
Jan-27-25 04:24PM	Akero Therapeutics Stock Nearly Doubles Pulling 89bio Higher On Positive MASH Study (Investor's Business Daily) +26.23%
04:12PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Jan-13-25 08:00AM	89bio Provides Business Update and Outlook for 2025 (GlobeNewswire)
Dec-19-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.62% +12.94%
Dec-04-24 01:02PM	Why Is 89bio, Inc. (ETNB) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-29-24 01:30PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 04:05PM	89bio to Participate in the 7th Annual Evercore HealthCONx Conference (GlobeNewswire)
Nov-15-24 08:05AM	89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024 (GlobeNewswire) -9.37%
Nov-12-24 11:58PM	89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -9.95%
04:01PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Nov-07-24 04:05PM	89bio Reports Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Nov-05-24 04:05PM	89bio to Participate in the UBS Global Healthcare Conference (GlobeNewswire) +10.18%
Nov-02-24 12:00PM	Madrigal, 89Bio jump after Novos semaglutide shows promise in MASH (TipRanks)
Nov-01-24 04:08PM	Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH (Investor's Business Daily) +17.48%
Oct-18-24 01:01AM	Suvretta Capital Management's Strategic Reduction in 89bio Inc Holdings (GuruFocus.com)
Oct-17-24 01:05PM	State Street Corp's Strategic Acquisition in 89bio Inc (GuruFocus.com)
Oct-15-24 08:30AM	89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting 2024 (GlobeNewswire)
Oct-11-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-30-24 04:05PM	89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference (GlobeNewswire)
Sep-19-24 04:03PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-16-24 04:05PM	89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer (GlobeNewswire)
Sep-04-24 04:15PM	NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth (GlobeNewswire)
Aug-29-24 08:00AM	89bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-09-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-07-24 08:00AM	89bio Appoints Francis Sarena as Chief Operating Officer (GlobeNewswire)
Aug-05-24 09:55PM	ETNB Stock Earnings: 89bio Beats EPS for Q2 2024 (InvestorPlace) -5.84% -5.36%
04:05PM	89bio Reports Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
08:00AM	89bio Appoints Charles McWherter, Ph.D., to its Board of Directors (GlobeNewswire)
Jul-12-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-14-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.60%
May-22-24 04:05PM	89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress (GlobeNewswire) -8.40%
May-14-24 08:00AM	89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis (GlobeNewswire)
May-10-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:16PM	89bio Inc (ETNB) Reports Increased Losses in Q1 2024 Despite Advancements in Clinical Trials (GuruFocus.com)
May-09-24 10:54PM	ETNB Stock Earnings: 89bio Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 11:56PM	Jump on the Bandwagon, Says Bank of America About These 2 Stock Picks (TipRanks)
04:05PM	89bio to Participate in the BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-06-24 12:00PM	All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy (Zacks)
May-02-24 04:05PM	89bio to Host Key Opinion Leader Webinar on Pegozafermin's Opportunity in Advanced MASH (GlobeNewswire)
Apr-17-24 04:05PM	89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors (GlobeNewswire)
Apr-05-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-03-24 07:01PM	89bio Inc CEO Rohan Palekar Sells 52,718 Shares (GuruFocus.com)
Mar-27-24 08:00AM	89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis (GlobeNewswire)
Mar-18-24 07:00AM	Ozempic Cant Do It AllA Potential New Blockbuster Is a Reminder of That (The Wall Street Journal) -6.80%
Mar-13-24 07:07AM	13 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Mar-12-24 08:00AM	89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis (GlobeNewswire)
Mar-08-24 04:05PM	89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-07-24 01:34PM	Hedge Fund and Insider Trading News: Ray Dalio, Bill Ackman, Crispin Odey, Glen Kacher, Julian Robertson, Nelson Peltz, Brevan Howard Asset Management, SLR Investment Corp. (SLRC), 89bio, Inc. (ETNB), and More (Insider Monkey) +7.34%
Mar-05-24 04:05PM	89bio to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire) -14.81%
09:55AM	Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade (Zacks)
09:30AM	89BIO (ETNB) Just Overtook the 200-Day Moving Average (Zacks)
Mar-04-24 04:04PM	Why Akero Rocketed And Pulled Rival 89bio Higher On Results In Liver Disease Treatment (Investor's Business Daily) +9.11%
12:30PM	Data Suggests Makers of Fatty Liver Treatments Wont Be Displaced by Obesity Drugs (The Wall Street Journal)
09:23AM	Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment (Investor's Business Daily)
Mar-02-24 04:31AM	89bio Inc (ETNB) Reports Increased R&D Spend and Strengthened Cash Position in Q4 and Full ... (GuruFocus.com)
Feb-29-24 04:05PM	89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) +10.03%
Feb-22-24 03:55AM	11 Best Small-Cap Growth Stocks to Invest In (Insider Monkey)
Feb-06-24 04:05PM	89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -17.04%
Feb-05-24 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-18-24 09:35AM	89BIO (ETNB) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Jan-10-24 09:55AM	Does 89BIO (ETNB) Have the Potential to Rally 168.77% as Wall Street Analysts Expect? (Zacks)
Dec-19-23 04:05PM	89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.71%
Dec-12-23 07:30AM	89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-07-23 07:00AM	89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-06-23 04:36PM	89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
Dec-04-23 07:00AM	89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024 (GlobeNewswire) +7.74%
Nov-27-23 08:00AM	89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH) (GlobeNewswire)

89bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. Its product pipeline includes pegozafermin, FGF21, NASH, and SHTG. The company was founded on January 18, 2018 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Le-Nguyen Quoc	See Remarks	Apr 15 '25	Sale	5.95	15,329	91,208	328,323	Apr 17 04:05 PM
QUOC LE-NGUYEN	Officer	Apr 15 '25	Proposed Sale	5.95	15,329	91,171		Apr 15 04:06 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jan 30 '25	Buy	8.75	5,714,285	49,999,994	19,554,319	Feb 03 05:38 PM
McWherter Charles	Director	Jan 22 '25	Buy	6.71	10,000	67,100	25,000	Jan 23 07:38 PM
McWherter Charles	Director	Jan 21 '25	Buy	6.55	5,000	32,750	15,000	Jan 23 07:38 PM
Le-Nguyen Quoc	See Remarks	Jan 15 '25	Sale	6.49	10,963	71,150	271,833	Jan 17 04:01 PM
QUOC LE-NGUYEN	Officer	Jan 15 '25	Proposed Sale	6.49	10,963	71,110		Jan 15 04:13 PM
PALEKAR ROHAN	Chief Executive Officer	Dec 06 '24	Buy	7.89	5,000	39,450	471,236	Dec 10 06:02 AM
McWherter Charles	Director	Dec 05 '24	Buy	8.00	10,000	80,000	10,000	Dec 09 06:01 AM
PALEKAR ROHAN	Chief Executive Officer	Nov 22 '24	Buy	8.35	10,000	83,500	466,236	Nov 25 06:05 AM
Le-Nguyen Quoc	See Remarks	Oct 30 '24	Sale	8.12	27,955	226,995	187,796	Nov 01 04:01 PM
QUOC LE-NGUYEN	Officer	Oct 30 '24	Proposed Sale	8.12	27,955	226,972		Oct 30 04:20 PM

ABCL

AbCellera Biologics Inc

ETNB

89bio Inc

Upgrade your FINVIZ experience